CytomX Therapeutics Company Insiders

CytomX Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of 0.0978 % which means that it generated a profit of $0.0978 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.6676 %, meaning that it created $0.6676 on every $100 dollars invested by stockholders. CytomX Therapeutics' management efficiency ratios could be used to measure how well CytomX Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. At this time, CytomX Therapeutics' Return On Tangible Assets are fairly stable compared to the past year. Return On Capital Employed is likely to rise to 0.68 in 2026, despite the fact that Return On Equity is likely to grow to (59.75). At this time, CytomX Therapeutics' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 19.1 M in 2026, whereas Non Currrent Assets Other are likely to drop slightly above 730.6 K in 2026. Common Stock Shares Outstanding is likely to drop to about 51.9 M in 2026. Net Loss is likely to drop to about (109.5 M) in 2026CytomX Therapeutics holds a total of 169.44 Million outstanding shares. The majority of CytomX Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in CytomX Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in CytomX Therapeutics. Please pay attention to any change in the institutional holdings of CytomX Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it. Some institutional investors establish a significant position in stocks such as CytomX Therapeutics in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of CytomX Therapeutics, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits.

CytomX Therapeutics Workforce Comparison

The company has Profit Margin (PM) of 0.25 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of (2.64) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $2.64.

CytomX Therapeutics Insider Trading History

CytomX Therapeutics Notable Stakeholders

String symbol = request.getParameter("s");

The success or failure of an entity such as CytomX Therapeutics often depends on how effective the management is. CytomX Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CytomX management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CytomX management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.

Please note, the imprecision that can be found in CytomX Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of CytomX Therapeutics. Check CytomX Therapeutics' Beneish M Score to see the likelihood of CytomX Therapeutics' management manipulating its earnings.

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.